After the breakneck pace of development in the digital health category during the pandemic, 2023 looks like it could be a pivotal year, with financing levels falling and t
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh